A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

Inclusion Criteria: 1. Agree to follow the experimental treatment plan and visit plan, join the group voluntarily, and sign a written informed consent form; 2. Age ≥ 18 years old when signing the informed consent form; 3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1; 4. The expected survival time is at least 12 weeks; 5. According to the evaluation of RECIST 1.1 standard, the subjects enrolled have at least one measurable Target lesion; 6. Subject has adequate organ and bone marrow function，Conforming to laboratory test results: 7. Males with fertility and females of childbearing age are willing to take effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug (including abstinence, intrauterine device, various hormonal contraception, correct use of contraception Sets，etc）; Women of childbearing age include pre-menopausal women and women within 2 years after menopause. Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered. Exclusion Criteria: 1. Have received other unmarketed clinical research drugs or treatments within 4 weeks before using the research drug for the first time; 2. Patients with active infection and currently requiring intravenous anti-infective treatment； 3. Those who have clinically uncontrollable pleural effusion, pericardial effusion , requiring repeated drainage or medical intervention; 4. The patient has a Medical history of immunodeficiency, including HIV antibody positive； 5. Women during pregnancy or lactation; 6. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.